AI-generated summary
The authors reviewed 26 studies (nine in vitro, 13 in vivo, four clinical) on photobiomodulation for preventing or treating radiation induced fibrosis. Preclinical studies reported beneficial cellular effects and clinical studies reported functional improvements, but the authors state that high-quality clinical trials are needed to validate clinical efficacy.
- Studies included
- 26
- Who or what was studied
- Cancer survivors with radiation induced fibrosis, plus fibroblast cells and fibrosis of any origin in in vitro and in vivo studies
- Limits stated in the abstract
- The abstract states that clinical evidence is limited and that high-quality clinical trials are necessary, and most included studies were preclinical.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background
Radiation induced fibrosis (RIF) is a chronic progressive disabling side effect of radiation therapy in cancer survivors with limited therapeutic options. Photobiomodulation therapy (PBMT) is being propagated as a non-invasive therapeutic option but has limited evidence. This scoping review aims to summarize the effects and mechanisms of PBMT in the prevention and treatment of RIF.
Methods
A systematic search was conducted across five databases (PubMed, Scopus, EBSCO, ProQuest, LILACS), and three other platforms (Google Scholar, ResearchGate, Academia.edu). Retrieved studies underwent independent title, abstract, full text screening and data extraction. Quality analysis was performed for human studies to assess methodological rigor.
Results
The review identified three studies that specifically focused on RIF. Since induction of RIF is not common for in vitro and in vivo studies, the screening was expanded to include studies targeting fibroblast cells or fibrosis of any origin. The revised strategy led to inclusion of 26 studies (nine in vitro, 13 in vivo, and four clinical studies). Of these, 20 studies focused on the prevention of fibrosis, while six addressed its treatment. Preclinical studies demonstrated the beneficial effects of PBMT at different phases of fibrosis at cellular level. Clinical studies demonstrated functional improvements. Mechanisms include modulation of inflammatory pathways, fibroblast to myofibroblast conversion, collagen production, reduction of oxidative stress, and regulation of extracellular matrix remodeling.
Conclusion
PBMT demonstrates potential as a non-invasive, safe therapeutic option for RIF, supported by extensive preclinical evidence. However, high-quality clinical trials are necessary to validate its clinical efficacy. IMPLICATION: PBMT offers a promising intervention for managing RIF, with potential to enhance body image, self-confidence, functional abilities, and overall quality of life for cancer survivors. This review underscores the need for further research to translate these findings into clinical practice.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Photobiomodulation, Light-emitting diode, Oxidative stress, Collagen. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.